Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Asymmetric Reduction. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN107794282B reveals a high-yield biocatalytic route for Crizotinib intermediates using Geotrichum candidum, offering superior purity and cost efficiency for API manufacturing.
Patent CN102925500A enables high-purity chiral ester synthesis via yeast biocatalysis, offering cost-effective and scalable pharmaceutical intermediate solutions for global supply chains.
Patent CN104232696A reveals biocatalytic method for high-purity chiral alcohol. Offers cost reduction and supply chain reliability for pharmaceutical manufacturing.
Patent CN106380409A reveals a cost-effective asymmetric reduction route for Levalbuterol. Enhance supply chain reliability with scalable, high-purity pharmaceutical intermediate production capabilities.
Patent CN108570460B discloses novel SDR mutants enabling high-selectivity biocatalytic reduction of acetophenone derivatives, offering a greener alternative for pharmaceutical intermediate manufacturing.
Patent CN112176019B details a high-yield biocatalytic route for (R)-1-(3-trifluoromethylphenyl) ethanol using recombinant E. coli and deep eutectic solvents, ensuring >99.9% e.e. and scalable production for neuroprotective intermediates.
Novel chiral epoxy propyl benzo-heterocycle synthesis for ROMK inhibitors. High ee, scalable route for pharmaceutical intermediates supply.
Novel patent CN119060034A offers high-yield morpholine synthesis without chiral resolution ensuring cost-effective and reliable supply chain solutions for global pharmaceutical manufacturers.
Novel synthesis method for Upadacitinib intermediate ensures high optical purity and scalable production for pharmaceutical supply chains globally.
Patent CN103773724B reveals biocatalytic route for high-purity chiral alcohol. Enhances supply chain reliability and reduces manufacturing costs significantly.
Patent CN102827030A details a safe, high-yield route for (3R,5R)-3,5-dihydroxy-6-cyanohexanoate, offering significant cost reduction and supply chain reliability for pharmaceutical manufacturers.
Patent CN109182410B details a high-yield biocatalytic route for chiral piperidine intermediates, offering significant cost reduction in API manufacturing and superior supply chain reliability.
Patent CN113174377A reveals stable carbonyl reductase mutants for high-yield diltiazem intermediate synthesis, offering cost-effective biocatalysis solutions.
Patent CN113200948A reveals a cost-effective copper-catalyzed route for chiral phthalides, offering high enantioselectivity and supply chain advantages for pharmaceutical manufacturers.
Novel Aeromonas caviae B18 strain enables high-purity chiral intermediate production with reduced costs and simplified downstream processing for pharma.
Patent CN105039436A details biocatalytic synthesis offering high yield and purity. This method ensures supply chain stability and cost efficiency for global pharmaceutical manufacturing partners.
Novel synthesis of substituted biphenyls for cholesterol treatment. Optimized reduction and cyclization routes ensure high purity and scalable supply for global pharmaceutical partners.
Patent CN101469318A enables high-purity (R)-phenylethylene glycol via dual-enzyme coupling, offering cost reduction and supply chain reliability for pharmaceutical manufacturing.
Patent CN113481175B discloses OYE2p mutants for stereoselective citral reduction. Discover cost-effective biocatalysis solutions for flavor and fragrance intermediates.
Patent CN1100410A details a novel route for (+)-2-(3,4-dichlorophenyl)-4-hydroxybutylamine using N-methylglucamine resolution and borane reduction for high-purity tachykinin antagonists.